IL-31 / PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT

• Main Authors: KANEKO AKIHISA, KITAMURA HIDETOMO, YAMAMOTO YUMI, MIHARA RYOSUKE, SAITO TOMOHISA, HIGUCHI YOSHINOBU, MATSUSHITA HIROAKI, HIROKAWA KEIKO, IWAYANAGI YUKI
• Format: Patent
• Language: English; Korean
• Published: 12.03.2024
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

비한정적인 일 실시태양에 있어서, IL-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물로서, 상기 IL-31 안타고니스트는, 0.1mg∼1000mg/body/1일∼12주, 바람직하게는 0.1mg∼1000mg/body/2주, 0.1mg∼1000mg/body/4주, 또는 0.1mg∼1000mg/body/8주로, 아토피성 피부염에 이환되었거나, 또는 이환되어 있을 우려가 있는 대상에게 등량이고 또한 동일한 투여 간격으로 반복 투여되는, 의약 조성물. In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.